skitahoe
4 minutes ago
Hoskuld, if you review the trials run at UCLA you'll find that adding Poly-ICLC to DCVax-L improves 5 year survival to 50% or greater, but without DCVax the Poly-ICLC is ineffective in GBM. It's uncertain that the same synergy exists in other solid cancers, and further trials will certainly be comi